About IMIDomics
IMIDomics is a company based in San Francisco (United States) founded in 2015 by Sara Marsal.. IMIDomics has raised $16.5 million across 4 funding rounds from investors including Evotec, UCB and European Union. IMIDomics offers products and services including IMID Drug Pipeline and IMID-Biobank. IMIDomics operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter San Francisco, United States
- Founders Sara Marsal
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Imidomics Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$16.5 M (USD)
in 4 rounds
-
Latest Funding Round
-
Investors
Evotec
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of IMIDomics
IMIDomics offers a comprehensive portfolio of products and services, including IMID Drug Pipeline and IMID-Biobank. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops targeted medicines for immune-mediated inflammatory diseases using data.
Manages clinical and biomolecular data for drug discovery applications.
Unlock access to complete
Unlock access to complete
Funding Insights of IMIDomics
IMIDomics has successfully raised a total of $16.5M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(01 Jan 2020)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Series A - IMIDomics | Valuation |
investors |
|
| Feb, 2022 | Amount | Series A - IMIDomics | Valuation | Evotec |
|
| Jul, 2021 | Amount | Series A - IMIDomics | Valuation | DNS Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in IMIDomics
IMIDomics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Evotec, UCB and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by DNS Capital.
|
Founded Year | Domain | Location | |
|
Growth-equity investments are managed by the private investment firm.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on multiple sectors
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by IMIDomics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - IMIDomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Imidomics Comparisons
Competitors of IMIDomics
IMIDomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Imidomics
Frequently Asked Questions about IMIDomics
When was IMIDomics founded?
IMIDomics was founded in 2015 and raised its 1st funding round 5 years after it was founded.
Where is IMIDomics located?
IMIDomics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of IMIDomics?
Fred Craves is the current CEO of IMIDomics.
Is IMIDomics a funded company?
IMIDomics is a funded company, having raised a total of $16.5M across 4 funding rounds to date. The company's 1st funding round was a Series A of $16.5M, raised on Jan 01, 2020.
What does IMIDomics do?
Founded in 2015 and based in San Francisco, United States, IMIDomics operates in the biotechnology sector. Exclusive data access is combined with biological insights to enable precision discovery of treatments for immune-mediated inflammatory diseases. Operations focus on targeting specific mechanisms in these conditions, with medicines developed to address unmet needs in inflammatory disorders.
Who are the top competitors of IMIDomics?
IMIDomics's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
What products or services does IMIDomics offer?
IMIDomics offers IMID Drug Pipeline and IMID-Biobank.
Who are IMIDomics's investors?
IMIDomics has 7 investors. Key investors include Evotec, UCB, European Union, Bristol-Myers Squibb, and DNS Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.